Local immunomodulation for cancer therapy: Providing treatment where needed

In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Fransen, Marieke F, Ossendorp, Ferry, Arens, Ramon, Melief, Cornelis JM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897564/
https://www.ncbi.nlm.nih.gov/pubmed/24490127
http://dx.doi.org/10.4161/onci.26493
_version_ 1782300256144195584
author Fransen, Marieke F
Ossendorp, Ferry
Arens, Ramon
Melief, Cornelis JM
author_facet Fransen, Marieke F
Ossendorp, Ferry
Arens, Ramon
Melief, Cornelis JM
author_sort Fransen, Marieke F
collection PubMed
description In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy.
format Online
Article
Text
id pubmed-3897564
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38975642014-01-31 Local immunomodulation for cancer therapy: Providing treatment where needed Fransen, Marieke F Ossendorp, Ferry Arens, Ramon Melief, Cornelis JM Oncoimmunology Author's View In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. Landes Bioscience 2013-11-01 2013-10-10 /pmc/articles/PMC3897564/ /pubmed/24490127 http://dx.doi.org/10.4161/onci.26493 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Fransen, Marieke F
Ossendorp, Ferry
Arens, Ramon
Melief, Cornelis JM
Local immunomodulation for cancer therapy: Providing treatment where needed
title Local immunomodulation for cancer therapy: Providing treatment where needed
title_full Local immunomodulation for cancer therapy: Providing treatment where needed
title_fullStr Local immunomodulation for cancer therapy: Providing treatment where needed
title_full_unstemmed Local immunomodulation for cancer therapy: Providing treatment where needed
title_short Local immunomodulation for cancer therapy: Providing treatment where needed
title_sort local immunomodulation for cancer therapy: providing treatment where needed
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897564/
https://www.ncbi.nlm.nih.gov/pubmed/24490127
http://dx.doi.org/10.4161/onci.26493
work_keys_str_mv AT fransenmariekef localimmunomodulationforcancertherapyprovidingtreatmentwhereneeded
AT ossendorpferry localimmunomodulationforcancertherapyprovidingtreatmentwhereneeded
AT arensramon localimmunomodulationforcancertherapyprovidingtreatmentwhereneeded
AT meliefcornelisjm localimmunomodulationforcancertherapyprovidingtreatmentwhereneeded

Ejemplares similares